8-K: Exicure Reports Full Year 2024 Financial Results Amid Strategic Review

Exicure, Inc. reports its full year 2024 financial results, highlighting a reduced net loss and ongoing exploration of strategic alternatives after ceasing R&D activities.

Summary

• Exicure, Inc., a biotechnology company, announced its full year 2024 financial results.
• The company significantly reduced its research and development activities in September 2022 and is exploring strategic alternatives to maximize stockholder value.
• As of December 31, 2024, Exicure had $12.5 million in cash and cash equivalents, compared to $0.8 million at the end of 2023.
• The company states that its current liquidity may not be sufficient to fund operations for the next 12 months.
• Additional financing will be needed to fund ongoing operations and the exploration of strategic alternatives.
• Research and development expenses were $0 for 2024, compared to $1.4 million in 2023, reflecting the stoppage of clinical and preclinical activities.
• General and administrative expenses decreased to $5.4 million in 2024 from $11.7 million in 2023, due to lower separation pay, payroll, legal fees, and facility costs.
• The company recorded a $0.6 million increase in litigation legal expenses due to accruals related to a securities litigation lawsuit.
• Exicure sold samples of its clinical products and certain assets, including its biotechnology intellectual property, to a private biopharmaceutical company.
• The company's net loss for 2024 was $(9.7) million, compared to a net loss of $(16.9) million in 2023.
• Management expresses substantial doubt about the company's ability to continue as a going concern without additional financing.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's going concern warning, need for additional financing, and cessation of R&D activities, despite some improvements in cash position and reduced net loss.

Positives

• Cash position significantly improved to $12.5 million.
• Net loss decreased by $7.2 million year-over-year.
• General and administrative expenses were significantly reduced.
• The company generated revenue from the sale of clinical products and assets.

Negatives

• The company's liquidity may not be sufficient to fund operations for the next 12 months.
• There is substantial doubt about the company's ability to continue as a going concern.
• Research and development activities have been halted.
• The company incurred litigation legal expenses of $0.6 million.

Risks

• The company needs additional financing to fund operations and strategic alternatives.
• There is no assurance that additional financing will be available or on acceptable terms.
• The company's ability to continue as a going concern is in doubt.
• The company faces risks and uncertainties that could cause actual results to differ from forward-looking statements, as detailed in their SEC filings.

Future Outlook

The company is exploring strategic alternatives to maximize stockholder value and requires additional financing to fund ongoing operations. Management expresses doubt about the company's ability to continue as a going concern without additional funding.

Management Comments

• The Company continues to engage in a broader exploration of strategic alternatives.
• Our current liquidity may not be sufficient to fund operations for the next 12 months.
• Additional financing will be needed to fund our ongoing operations and exploration of strategic alternatives and pursue any alternatives that we identify.
• Management believes that the Company's existing cash and cash equivalents may not be sufficient to fund operations.
• There is substantial doubt about our ability to continue as a going concern.

Industry Context

Exicure's situation reflects the challenges faced by early-stage biotechnology companies, particularly in securing funding and navigating strategic shifts. The company's move to explore strategic alternatives is a common response to financial constraints and changing market conditions in the biotech industry.

Comparison to Industry Standards

• Given Exicure's shift away from R&D and focus on strategic alternatives, direct comparison to other biotech companies is difficult.
• Companies like Dicerna Pharmaceuticals (acquired by Novo Nordisk) and Alnylam Pharmaceuticals, which focus on RNAi therapeutics, represent the type of companies Exicure historically resembled.
• However, these companies are in active development and commercialization phases, unlike Exicure's current state.
• Exicure's current strategy is more akin to companies undergoing restructuring or seeking mergers and acquisitions, where financial metrics and asset valuations are key considerations.

Legal Proceedings

• The company recorded an increase in litigation legal expense due to accruals related to a securities litigation lawsuit.

Stakeholder Impact

• Shareholders face uncertainty due to the company's strategic review and need for additional financing.
• Employees have been impacted by the reduction in force and suspension of R&D activities.
• The company's customers and suppliers are affected by the change in business operations.

Next Steps

• The company will continue to explore strategic alternatives to maximize stockholder value.
• The company will seek additional financing to fund ongoing operations.

Key Dates